Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

FIVP calls for urgent review of CMA remedies
“We expect the CMA’s proposed remedy package to have a disproportionately negative effect on independent businesses" - Rita Dingwall, Chair of FIVP.
Independent practices fear for the future of their businesses.

The Federation of Independent Veterinary Practices (FIVP) has called on the Competition and Markets Authority (CMA) to urgently review its proposed remedies for the veterinary sector.

FIVP, which is a main party in the CMA’s market investigation, warns that the existing remedies will disproportionately impact independent practices and threaten their viability.

The organisation has particularly cautioned against the CMA’s approach to prescriptions and online pharmacies. Under the regulator’s current plans, veterinary professionals could be asked to direct clients to online pharmacies for ‘savings’ on their medications.

FIVP states that many online pharmacies are owned by large veterinary groups, which are taking this revenue from independently owned practices.

It explains that, especially for these independent practices, medicine sales from a vital part of their income. It is through medicine sales that these practices are able to offer veterinary procedures at more affordable prices.

This shift to online pharmacies could see independent practices forced to “repackage” their offerings to clients. While medicine costs may fall, a rise in professional fees could mean that, at best, overall costs to the client remain the same.

However, once increased administrative fees and the loss of income from medicines is factored in, FIVP estimates that overall prices could rise as much as 12 per cent over inflation.

FIVP’s Impact Assessment found that approximately 90 per cent of respondents disagreed with the CMA’s approach to online pharmacies. Nearly 95 per cent expected the remedies to negatively affect their finances, while 85 per cent said they would cause confusion and unexpected fees for clients.

Rita Dingwall, FIVP chair, said: “We expect the CMA’s proposed remedy package to have a disproportionately negative effect on independent businesses, potentially threatening the viability of community practices across the country. Our impact assessment survey found that independent veterinary business owners overwhelmingly disagreed with the CMA medicines remedies.

“As the CMA’s statutory deadline approaches, FIVP will continue to engage with the CMA to encourage a remedy package that will result in a fair market for all veterinary businesses and one that supports animal welfare”

FIVP’s full statement has been published here. You can also find FIVP’s full response to the remedies and its Impact Assessment on the FIVP website.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.